Please assess the completion status of the following clinical trial:

Trial Title: Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic hormone refractory prostate cancer.~* Eastern Cooperative Oncology Group (ECOG) Performance status of 0-1.~* testosterone \<50ng/dL. Patients must continue primary androgen deprivation with an LHRH analogue if they have not undergone orchiectomy.~* Progressive disease after androgen deprivation.~Exclusion Criteria:~* Patients whose clinical condition would make chemotherapy clearly indicated.~* Patients who have received systemic chemotherapy for the treatment of metastatic disease.~* Peripheral neuropathy \> Grade 1~* Prior anti-angiogenic therapy, including thalidomide.~* Patients with inadequate recovery from any prior surgical procedure, or patients having undergone any major surgical procedure or radiation within 4 weeks prior to study entry.~* Patients who have received radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.~* Patients with known brain metastases or history of brain metastases.~* History of stroke within 6 months of treatment or other significant neurological limitations.~* Patients who have received more than 2 prior investigational treatments.~* Uncontrolled intercurrent illness~* Patients with a history of a myocardial infarction within the prior 6 months or, hospitalizations for decompensated congestive heart failure within the prior 6 months, or history of significant / symptomatic cardiac arrhythmias

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)

Based on this trial design, predict the completion outcome and termination type (if applicable).